Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MEDICI - t(11;14) and BCL2 Expression in Patients With Multiple Myeloma: Prevalence, Stability Across Lines of Therapy and Concordance Across Sample Types

NCT04721002 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04721002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04721002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MEDICI - t(11;14) and BCL2 Expression in Patients With Multiple Myeloma: Prevalence, Stability Across Lines of Therapy and Concordance Across Sample Types
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
July 7, 2021
Completion date
September 30, 2023
Enrollment
514 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma (mm)